University of Connecticut, Farmington, CT, USA.
Maturitas. 2012 Dec;73(4):275-9. doi: 10.1016/j.maturitas.2012.08.009. Epub 2012 Sep 25.
Breast cancer is a common diagnosis and the majority of women treated will be cured. Women with early stage breast cancer may be at increased risk for osteoporosis due to anticancer therapies. Chemotherapy induced amenorrhea and the use of anti-estrogens can promote bone loss; thus, the management of bone health in women with breast cancer is an important component of survivorship care. Osteoporosis is considered a "silent" disease as there are often no discrete warning signs, until a fracture occurs; therefore, clinicians must be cognizant of the underlying risk for osteoporosis and co-morbid conditions and/or medications that accelerate risk of fracture. Breast cancer therapies that effect bone, screening for bone loss and interventions to mitigate the treatment toxicities are reviewed.
乳腺癌是一种常见的诊断，大多数接受治疗的女性都可以被治愈。由于抗癌治疗，早期乳腺癌女性可能会增加骨质疏松症的风险。化疗引起的闭经和使用抗雌激素药物会促进骨质流失；因此，乳腺癌女性的骨骼健康管理是生存护理的一个重要组成部分。骨质疏松症被认为是一种“无声”的疾病，因为通常没有明显的警告信号，直到发生骨折；因此，临床医生必须认识到骨质疏松症和合并症的潜在风险，以及加速骨折风险的药物。本文回顾了影响骨骼的乳腺癌治疗方法、骨质疏松症筛查和减轻治疗毒性的干预措施。
